×
About 10,598 results

Pneumonia
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/298103

Globally, pneumonia kills more children younger than 5 years old each year than any other infectious disease, such as HIV infection, malaria, or tuberculosis.

Pneumococcal Vaccine Uptake Remains Low Among Vulnerable Canadians
https://www.medscape.com/viewarticle/983922

Nov 11th, 2022 - Pneumococcal vaccination uptake remains low among high-risk adults in Canada, including those aged 65 years or older and patients with chronic conditions, according to a new report. Nearly half of older adults — and 80% of patients aged 47 to 64 years who have underlying medical conditions — have never received a pneumococcal vaccine, which places them at a disproportionately higher risk for se...

Monoclonal Antibodies an Option for Oncohematology Patients
https://www.medscape.com/viewarticle/983538

Nov 4th, 2022 - MADRID, Spain — Monoclonal antibodies are positioned as the best option against SARS-CoV-2, mainly in pre-exposure prophylaxis in adults and in patients without supplemental oxygen at high risk of progression. Although viral variants are the greatest threat to their effectiveness, in oncohematological patients, these drugs continue to be very powerful and may be combined with other therapeutic ...

Hiccups in Patients With Cancer Often Overlooked, Undertreated
https://www.medscape.com/viewarticle/983539

Nov 4th, 2022 - As many as 40% of patients with cancer develop hiccups — often unbeknownst to their oncologist. But even if recognized, hiccups may not be treated effectively, according to a national survey of cancer care clinicians. When poorly controlled, persistent hiccups can affect a patient's quality of life, with 40% of survey respondents considering chronic hiccups "much more" or "somewhat more" severe...

COVID Disrupted Measles Vaccinations in Africa and Now Cases Are Surging
https://www.medscape.com/viewarticle/982976

Oct 26th, 2022 - BUNDUNG, Gambia/LONDON (Reuters) - Clutching an umbrella, medical records and her two-year-old daughter, Kani Fall negotiated the brown puddles lapping at the hospital gate, the final hurdle in a two-hour, rain-soaked journey to her nearest vaccination clinic in western Gambia. Fall waited with dozens of mothers and babies in the flooded courtyard of Bundung Hospital. Then a doctor emerged with...

Upfront Empiric CAP Antimicrobial Therapy Linked to Less VAP in Severe COVID-19
https://www.pulmonologyadvisor.com/home/meetings/chest-2022/upfront-empiric-cap-antimicrobial-therapy-linked-to-less-vap-in-severe-covid-19/
Pulmonology Advisor

Oct 19th, 2022 - In patients with severe SARS-CoV-2 infection who require invasive mechanical ventilation (MV), the early empiric administration of community-acquired pneumonia (CAP) antimicrobial therapy is associated with reduced rates of ventilator-associated pneumonia (VAP), according to research presented at the American College of Chest Physicians (CHEST) 2022 Annual Meeting, held October 16 to 19, in Nas...

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
https://clinicaltrials.gov/ct2/show/NCT04368728

Oct 14th, 2022 - This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals. The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part. The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-...

COVID-19 Persistence in Stool
https://clinicaltrials.gov/ct2/show/NCT04546776

Oct 14th, 2022 - Approaching participants will mainly be performed in two ways: the Norfolk and Norwich University Hospital (NNUH) online booking system for SARS-CoV-2 testing will have a link to the Quadram Institute Bioscience (QIB) study webpage, which will include the Participant Information Sheet (PIS). When the NHS testing service informs individuals of their test results by text message, the QIB study pa...

A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
https://clinicaltrials.gov/ct2/show/NCT04852289

Oct 14th, 2022 - STUDY DESCRIPTION: This study is to identify SARS-CoV-2 S protein specific CD8 T cells in the blood of COVID-19 vaccinated participants. Pfizer and Moderna made vaccines will be used in this study. As both vaccines are mRNA based encoding S protein of SARS-CoV-2 and require two doses, the CD8 T cell response is expected to be comparable. We will also measure general health factors using blood s...

Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
https://clinicaltrials.gov/ct2/show/NCT04924803

Oct 14th, 2022 - People who inject drugs (PWID) experience disproportionate risk of being infected with SARS-CoV-2, the virus that causes COVID-19. Unfortunately, due to stigma, fear of mistreatment, and other factors, PWID are far less likely to be vaccinated compared to other populations. African American and Latino populations also face disproportionate risk of infection and far greater COVID-19 death rates ...

Study of Lung Proteins in Patients With Pneumonia
https://clinicaltrials.gov/ct2/show/NCT00077909

Oct 14th, 2022 - OBJECTIVE: The objective of this study is to analyze bronchoalveolar lavage (BAL) fluid from patients with lung infiltrates in order to discover new biomarkers and protein/peptide expression patterns that are associated with specific types of pulmonary diseases and infections. Bronchoalveolar lavage (BAL) is a standard method to obtain lower airway samples to evaluate pulmonary infiltrates in o...

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
https://clinicaltrials.gov/ct2/show/NCT04283461

Oct 14th, 2022 - This is a phase I, open-label, dose-ranging clinical trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based va...

Respiratory COVID-19: A Randomized, Sham-Controlled Study
https://clinicaltrials.gov/ct2/show/NCT05166915

Oct 14th, 2022 - The UV Respiratory Tract Light Therapy Device is intended to emit energy in the UVA region of the spectrum in intubated patients to reduce the viral burden of SARS-CoV-2 (human pathogenic coronavirus (COVID-19)) in intubated patients. The System is to be used in conjunction with the current standard of care measures. The UV Respiratory Tract Light Therapy Device is intended to be used for 20 mi...

A Study to Learn About New COVID-19 RNA Vaccine Candidates as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Individuals
https://clinicaltrials.gov/ct2/show/NCT05472038

Oct 14th, 2022 - The purpose of this clinical trial is to learn about the safety, tolerability and immunogenicity of BNT162b, RNA-based SARS-CoV-2 vaccine candidates given as a booster dose in adults to prevent COVID-19. For all cohorts (groups of participants), this study is seeking participants who are healthy (who may have preexisting disease if it is stable); All participants will receive a single dose of t...

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study
https://clinicaltrials.gov/ct2/show/NCT05484882

Oct 14th, 2022 - STUDY DESCRIPTION The objective is to conduct a prospective natural history study of Coronavirus disease 2019 (COVID-19) among a community-based cohort of African Americans enrolled in GENE-FORECAST for whom we have comprehensive psychosocial, clinical, and genetic data collected at baseline. Participants will be invited to take part in a 20-minute computer-assisted telephone interview (CATI) o...

Investigation of Prognostic Biomarkers, Host Factors and Viral Factors for COVID-19 in Children
https://clinicaltrials.gov/ct2/show/NCT05576714

Oct 14th, 2022 - Background for COVID-19 associated encephalopathy/encephalitis in children The COVID-19 primarily cause the respiratory diseases, such as croup, bronchiolitis, or pneumonia, but it also can affect the nervous system. According to the data of 1,695 children and adolescents, from March 15, 2020, to December 15, 2020, hospitalized for COVID-19 in 61 hospitals in the United States, 365 (22%) were f...

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
https://clinicaltrials.gov/ct2/show/NCT05184218

Oct 14th, 2022 - IGM-6268 is an engineered Immunoglobulin M (IgM) antibody that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. This humanized pentameric IgM antibody has 10 binding sites to the spike protein and a J-chain to enable the formation of IgM pentamers. IGM-6268 is being developed as a treatment for or prophylaxis of symptoms associated with mild to moderate CO...

Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
https://clinicaltrials.gov/ct2/show/NCT05175625

Oct 14th, 2022 - This was a randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety and immunogenicity of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen) produced by CinnaGen Co. A total of 300 adult individuals received a single dose of either the SpikoGen vaccine or the saline placebo in a 5:1 ratio at 4 to 9 months after th...

Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
https://clinicaltrials.gov/ct2/show/NCT04944368

Oct 13th, 2022 - This is a phase II, randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, and immunogenicity of a candidate adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen) produced by CinnaGen Co. 400 adult individuals receive either SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) or saline placebo...

Genetics of COVID-19 Susceptibility and Manifestations
https://clinicaltrials.gov/ct2/show/NCT04371432

Oct 13th, 2022 - The current SARS-CoV-2 pandemic presents a serious challenge to public health. Individuals infected with SARS-CoV-2 experience extremes in symptomatology ranging from a complete lack of symptoms to rapidly worsening end-stage pulmonary disease. The explanatory mechanism underlying susceptibility to severe disease remains unknown. We hypothesize that underlying genetic factors are at least parti...